应用皮肤试验抑制指数评价阿伐斯汀的起效时间

目的皮肤试验抑制指数(Skin Test Inhibition Index,STII)是评价抗组胺药疗效的一个药效学指标,本试验以阿伐斯汀为例应用STII方法评价抗组胺药阿伐斯汀的起效时间。方法选择27例花粉症病人,分为阿伐斯汀组(24例)和安慰剂组(3例),并分别于服药前及服药30、90min后观察受试者的过敏原皮试反应,计算STII值,并将STII达到10的时间定为起效时间。结果安慰剂组前后过敏原皮试风团无显著差异,而阿伐斯汀组30、90min后,STII值分别为22.2、237.7。故可初步认为阿伐斯汀的起效时间小于30min。结论 STII可做为评价抗组胺药起效时间的客观指标之一。

Evaluation on onset time of acrivastine assayed with skin test inhibition index

objective Skin Test Inhibition index(STⅡ) is an pharmacodynamic assay method to evaluate the curative effect of antihistamine which is reliable and sensitive. STⅡ was used to assess the onset time of acrivastine in this investigation. Method 27 subjects with hay fever in off-season were selected. Subjects were divided into acrivastine group (24) or placebo control group (3). Artemisia allergen skin test were carried out before and after treatment in 30、90 minutes. The wheal reactions were recorded and calculated. According to STⅡ method, the STⅡ value were computed. The time needed to reach STⅡ 10 was defined as the onset time. Result The wheal showed no significant changes in placebo controlled subjects. The wheal size induced by Artemisia pollen extract where significantly inhibited after acrivastine treatment. The STⅡ were 22.2 and 237.7 after acrivastine administration in 30、90 minutes respectively. Therefor the onest time of acrivastine was within 30 minutes. Conclusion STⅡ can be an objective index to evaluate the onset time of antihistamines.